Hydroxychloroquine in lupus pregnancy

Arthritis and Rheumatism

Volumn 54, Issue 11, 2006, Pages 3640-3647

  Clowse, Megan E B ^a   Magder, Laurence ^b   Witter, Frank ^c   Petri, Michelle ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; HYDROXYCHLOROQUINE; PREDNISONE;

ADULT; ARTICLE; BIRTH DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE EXACERBATION; FEMALE; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PREGNANCY; PREGNANCY OUTCOME; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; SPONTANEOUS ABORTION; STILLBIRTH; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ABORTION, SPONTANEOUS; ADULT; ANTIRHEUMATIC AGENTS; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROXYCHLOROQUINE; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREDNISONE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, FIRST; PREMATURE BIRTH; PROSPECTIVE STUDIES; STILLBIRTH; TREATMENT OUTCOME;

EID: 33750955870     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22159     Document Type: Article

References (35)

1. Petri M. Hydroxychloroquine: past, present, future. Lupus 1998;7:65-7.
2. Fessler BJ, Alarcon GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW, et al, and the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-80.
3. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324:150-4.
4. Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al, and the Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 1998;7:80-5.
5. Petri M, Allbritton J. Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort. J Rheumatol 1993;20:650-6.
6. Hardy CJ, Palmer BP, Morton SJ, Muir KR, Powell RJ. Pregnancy outcome and family size in systemic lupus erythematosus: a case-control study. Rheumatology (Oxford) 1999;38:559-63.
7. Fraga A, Mintz G, Orozco J, Orozco J. Sterility and fertility rates, fetal wastage and maternal morbidity in systemic lupus erythematosus. J Rheumatol 1974;1:293-8.
8. Al-Herz A, Schulzer M, Esdaile JM. Survey of antimalarial use in lupus pregnancy and lactation. J Rheumatol 2002;29:700-6.
9. Ostensen M, Khamashta M, Lockshin M, Parke A, Brucato A, Carp H, et al. Anti-inflammatory and immunosuppressive drugs and reproduction [review]. Arthritis Res Ther 2006;8:209-28.
10. Paufique L, Magnard P. Retinal degeneration in 2 children following preventive antimalarial treatment of the mother during pregnancy. Bull Soc Ophtalmol Fr 1969;69:466-7.
11. Ullberg S, Lindquist NG, Sjostrand SE. Accumulation of chorioretinotoxic drugs in the foetal eye. Nature 1970;227:1257-8.
12. Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DL, Sebbough D, Wechsler, B, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2003;48:3207-11.
13. Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JL, Tura BR, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 2001;10:401-4.
14. Parke A, West B. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 1996;23:1715-8.
15. Klinger G, Morad Y, Westall CA, Laskin C, Spitzer KA, Koren G, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases [letter]. Lancet 2001;358:813-4.
16. Motta M, Tincani A, Faden D, Zinzini E, Chirico G. Antimalarial agents in pregnancy [letter]. Lancet 2002;359:524-5.
17. Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992;19:53-9.
18. Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy: the Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 1991;34:1538-45.
19. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
20. Ducharme J, Fieger H, Ducharme MP, Khalil SK, Wainer IW. Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. Br J Clin Pharmacol 1995;40:127-33.
21. Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 1989;27:771-9.
22. Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol 1996;87:163-8.
23. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
24. Dooley MA, Aranow C, Ginzler EM. Review of ACR renal criteria in systemic lupus erythematosus. Lupus 2004;13:857-60.
25. Wilson WA. Classification criteria for antiphospholipid syndrome. Rheum Dis Clin North Am 2001;27:499-505, v.
26. Clowse ME, Magder LS, Witter F, Petri M. Early risk factors for pregnancy loss in lupus. Obstet Gynecol 2006;107:293-9.
27. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52:514-21.
28. Motta M, Tincani A, Faden D, Zinzini E, Lojacono A, Marchesi A, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 2005;25:86-9.
29. Buchanan NM, Toubi E, Khamashta MA, Lima F, Kerslake S, Hughes GR. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 1996;55:486-8.
30. Levy M, Buskila D, Gladman DD, Urowitz MB, Koren G. Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 1991;8:174-8.
31. Costedoat-Chalumeau N, Amoura Z, Huong DL, Lechat P, Piette JC. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: review of the literature. Autoimmun Rev 2005;4:111-5.
32. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002;109:1377-82.
33. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000;62:385-92.
34. Buyon JP, Kalunian KC, Ramsey-Goldman R, Petri MA, Lockshin MD, Ruiz-Irastorza G, et al. Assessing disease activity in SLE patients during pregnancy. Lupus 1999;8:677-84.
35. Urowitz MB, Gladman DD, Farewell VT, Stewart J, McDonald J. Lupus and pregnancy studies. Arthritis Rheum 1993;36:1392-7.